Gland Pharma Sustainability Profile
Gland Pharma Limited, commonly referred to as Gland Pharma, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Established in 1978, the company has made significant strides in the development and manufacturing of high-quality injectable pharmaceuticals, particularly in the areas of oncology, anaesthesia, and critical care. With a strong presence in both domestic and international markets, Gland Pharma has earned a reputation for its robust product portfolio, which includes a range of generic injectables and complex formulations. The company is recognised for its commitment to quality and innovation, having achieved several key milestones, including successful partnerships with global healthcare providers. Gland Pharma's dedication to excellence positions it as a leader in the injectable segment, contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Gland Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gland Pharma's score of 21 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gland Pharma's reported carbon emissions
In 2024, Gland Pharma reported total carbon emissions of approximately 15,736,000 kg CO2e for Scope 1 and about 81,154,000 kg CO2e for Scope 2, resulting in a combined total of approximately 96,890,000 kg CO2e. This data reflects their global operations, including their headquarters in India. The company has shown a slight increase in emissions compared to 2023, where they recorded approximately 11,929,600 kg CO2e for Scope 1 and about 80,669,600 kg CO2e for Scope 2, totalling around 92,599,200 kg CO2e. Gland Pharma's emissions data is cascaded from its parent company, Gland Pharma Limited, indicating a corporate family relationship. However, the company has not set specific reduction targets or climate pledges, nor does it disclose Scope 3 emissions data. The absence of defined reduction initiatives suggests that Gland Pharma is currently focusing on monitoring its emissions without formal commitments to decrease them. Overall, Gland Pharma's emissions profile highlights the need for enhanced climate commitments and strategies to address their carbon footprint effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 12,579,300 | 00,000,000 | 00,000,000 |
| Scope 2 | 78,475,200 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Gland Pharma's Industry?
How Carbon Intensive is Gland Pharma's Location?
Gland Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Gland Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Boehringer Ingelheim Pharmaceuticals, Inc.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.